Nevertheless, we were able to exclude the idea that tumor cells are the main source of tumor lymphangiogenesis, because depletion of macrophages by the CDL treatment caused >80% reduction in VEGF-C/D expressions in the tumor mass compared to the control CL treatment. The gene discussed is SGMS2; the disease is neoplasm.